Suppr超能文献

利用行政数据研究将三级家庭检测纳入基于多导睡眠图的睡眠医学计划的成本影响。

Investigating Cost Implications of Incorporating Level III At-Home Testing into a Polysomnography Based Sleep Medicine Program Using Administrative Data.

机构信息

Medical Informatics, Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.

Division of Respirology, Critical Care and Sleep Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

出版信息

Can Respir J. 2017;2017:8939461. doi: 10.1155/2017/8939461. Epub 2017 Jul 16.

Abstract

OBJECTIVE

Obstructive sleep apnea is a common problem, requiring expensive in-lab polysomnography for proper diagnosis. Home monitoring can provide an alternative to in-lab testing for a subset of OSA patients. The objective of this project was to investigate the effect of incorporating home testing into an OSA program at a large, tertiary sleep disorders centre.

METHODS

The Sleep Disorders Centre in Saskatoon, Canada, has been incorporating at-home testing into their diagnostic pathways since 2006. Administrative data from 2007 to 2013 were extracted (10030 patients) and the flow of patients through the program was followed from diagnosis to treatment. Costs were estimated using 2014 pricing and were stratified by disease attributes and sensitivity analysis was applied.

RESULTS

The overall costs per patient were $627.40, with $419.20 for at-home testing and $746.20 for in-lab testing. The cost of home management would rise to $515 if all negative tests were required to be confirmed by an in-lab PSG.

DISCUSSION

Our review suggests that at-home testing can be cost-effective alternative to in-lab testing when applied to the correct population, specifically, those with a high pretest probability of obstructive sleep apnea and an absence of significant comorbidities.

摘要

目的

阻塞性睡眠呼吸暂停是一种常见问题,需要昂贵的实验室多导睡眠图检查进行正确诊断。家庭监测可为一部分 OSA 患者提供替代实验室测试的方法。本项目的目的是研究在大型三级睡眠障碍中心的 OSA 计划中纳入家庭测试的效果。

方法

加拿大萨斯卡通的睡眠障碍中心自 2006 年以来一直将家庭测试纳入其诊断途径。从 2007 年到 2013 年提取了行政数据(10030 名患者),并跟踪了患者通过该计划从诊断到治疗的流程。使用 2014 年的价格估算了成本,并按疾病特征进行分层,同时进行了敏感性分析。

结果

每位患者的总体成本为 627.40 加元,其中家庭测试为 419.20 加元,实验室测试为 746.20 加元。如果所有阴性测试都需要通过实验室 PSG 确认,则家庭管理的成本将增加到 515 加元。

讨论

我们的审查表明,当应用于正确的人群(即那些阻塞性睡眠呼吸暂停的术前可能性较高且无明显合并症的人群)时,家庭测试可以作为实验室测试的具有成本效益的替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e07/5534303/228c76f047da/CRJ2017-8939461.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验